人体内皮质受限的内皮素-1过度表达导致血管重塑和内皮质功能障碍
Farhad Amiri1, Agostino Virdis, Mario Fritsch Neves
1Experimental Hypertension, Clinical Research Institute of Montreal, Montreal, Quebec, Canada.
Circulation
|October 7, 2004
概括
来自内皮细胞的内甲素-1 (ET-1) 驱动血管重塑和功能障碍,独立于血压变化. 这项研究突出了ET-1的特点.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 血管生理学 血管生理学
背景情况:
- 内甲素 (ET) -1 是一个关键的血管收缩剂,与血管改造和心血管疾病有关.
- 血管内皮细胞是内源性ET-1的主要来源.
- 了解内皮衍生的ET-1的特定作用对于心血管病理生理学至关重要.
研究的目的:
- 研究内皮质衍生ET-1对心血管功能的直接影响.
- 建立一种小鼠模型来研究向ET-1在内皮中的过度表达的影响.
- 阐明ET-1影响血管健康的非血液动力学机制.
主要方法:
- 通过使用Tie-2促进体,生成具有内皮特异性人类preproET-1过度表达的转基因 (TG) C57BL/6小鼠.
- 将TG小鼠与10周大时的非转基因 (野生类型;WT) littermates进行比较.
- 评估ET-1水平,血压,血管改造,内皮功能,ET受体表达和氧化应激标志物.
主要成果:
- 与WT小鼠相比,TG小鼠的血管ET-1mRNA和血ET-1水平显著升高.
- 尽管血压正常,但TG小鼠在抵抗血管中表现出高缩重塑和内皮功能障碍.
- 在TG小鼠中观察到氧化应激增加,可能是通过NAD(P) H氧化酶激活,并改变了ET-1/ET-3反应.
结论:
- 内皮受限的ET-1过度表达会诱导血管结构重塑和内皮功能障碍.
- 这些效应发生在ET-1对血管系统的直接,非血液动力学作用中.
- 血管NAD(P) H氧化酶的激活是调解ET-1有害血管效应的关键机制.
更多相关视频
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K


